{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-24-000324","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.783638+00:00","generated_at":"2026-06-04T05:50:42.925200+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"IGC Pharma announces $3M private placement with Bradbury Asset Management at $0.34/share","bullets":["Issued 8,823,529 unregistered common shares at $0.34/share to Bradbury Asset Management on March 22, 2024.","Gross proceeds of $3 million to fund general corporate purposes and advance investigational drug IGC-AD1.","Closing subject to customary conditions including NYSE approval; shares not immediately tradable.","After issuance, IGC will have ~75,365,061 shares outstanding; piggyback registration rights granted."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-24-000324","json":"https://secwatch.observer/filing/0001185185-24-000324.json","markdown":"https://secwatch.observer/filing/0001185185-24-000324.md","text":"https://secwatch.observer/filing/0001185185-24-000324.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000324/0001185185-24-000324-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000324/igcpharma20240326_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:50:42.925200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ff7173f4cdae689abcbb2e1eb8a73aba891201a7","claim":"IGC Pharma, Inc. entered into 2024 Share Purchase Agreement with Bradbury Asset Management (Hong Kong) Limited valued at $3,000,000 (effective 2024-03-22).","evidence_excerpt":"On March 22, 2024, IGC Pharma, Inc. (“IGC” or the “Company”) entered into the 2024 Share Purchase Agreement (the “2024 SPA”) with Bradbury Asset Management (Hong Kong) Limited (“Bradbury”) relating to the sale and issuance by our company to the investors of an aggregate of 8,823,529 shares of our common stock, for a total purchase price of $3,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518524000324/0001185185-24-000324-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Bradbury Asset Management (Hong Kong) Limited"},{"label":"Value","value":"$3,000,000"},{"label":"Effective","value":"2024-03-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}